Startups
Sinemia takes aim at MoviePass again, with new $9.99 plan
Sinemia continues its campaign to take advantage of MoviePass’ high-profile struggles and win over the better-known movie ticket subscription service’s customers. Today, it announced a new plan priced at $9.99 per month.
MoviePass, after all, recently announced that it would be keeping its monthly subscription price at $9.95, but limiting subscribers to three films per month (with discounts on additional tickets).
The new Sinemia tier also includes three tickets each month, but it has the additional benefit of allowing subscribers to buy tickets for any 2D, non-IMAX screen, and to buy those tickets in advance. MoviePass, in contrast, is rotating the available films each day, and it requires subscribers to buy their tickets at the theater, on the same day as the screening.
Just a couple weeks ago, Sinemia announced a refer-a-friend program that rewards subscribers who convince their friends to leave other subscription services. The company makes no secret of the fact that it’s targeting MoviePass in particular — in today’s announcement, it describes the new plan as one that “matches MoviePass’ latest.”
Sinemia offers a variety of other options, ranging from $3.99 per month for one ticket, to $14.99 for three tickets, with IMAX and 3D access.
-
Entertainment6 days ago
Earth’s mini moon could be a chunk of the big moon, scientists say
-
Entertainment6 days ago
The space station is leaking. Why it hasn’t imperiled the mission.
-
Entertainment5 days ago
‘Dune: Prophecy’ review: The Bene Gesserit shine in this sci-fi showstopper
-
Entertainment4 days ago
Black Friday 2024: The greatest early deals in Australia – live now
-
Entertainment3 days ago
How to watch ‘Smile 2’ at home: When is it streaming?
-
Entertainment3 days ago
‘Wicked’ review: Ariana Grande and Cynthia Erivo aspire to movie musical magic
-
Entertainment2 days ago
A24 is selling chocolate now. But what would their films actually taste like?
-
Entertainment2 days ago
New teen video-viewing guidelines: What you should know